Lung EpiCheck Biomarkers Development Study

NCT06245876 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 6000

Last updated 2024-02-12

No results posted yet for this study

Summary

This study is part of the development of a non-invasive lung cancer screening test which aim to identify early-stage lung cancer in patients at high risk for lung cancer.

Conditions

Interventions

OTHER

Blood collection

Blood collection

Sponsors & Collaborators

  • Nucleix Ltd.

    lead INDUSTRY

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-17
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • United States
  • Hungary
  • Israel
  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06245876 on ClinicalTrials.gov